Skip to content

New Treatment for Donor Sites

New Treatment for Donor Sites

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00591916
Acronym
Donors
Enrollment
0
Registered
2008-01-11
Start date
2006-01-31
Completion date
2010-11-30
Last updated
2012-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn

Keywords

burn, donor site, grafting, scar

Brief summary

Primary research questions/Purpose of the Research. 1. Determine the short term (epidermal regeneration, reduction of pain, infections and length of stay) and long term (scarring, long term recovery, and cost of treatment) outcomes of Microbial Nanocellulose (NC) and fine mesh gauze impregnated with hyaluronan and thrombin (HT). 2. Determine if donor site treatment with NC and HT is as safe as the use of Scarlet Red ointment dressing. b. Describe the importance of the knowledge that you expect to gain from the research. To find a donor site dressing that has outcomes equal or better than that of scarlet red.

Interventions

DRUGApplication of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]

Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).

PROCEDUREBlood sample

Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery

PROCEDUREBiopsy

Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.

Sponsors

The University of Texas Medical Branch, Galveston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 90 Years
Healthy volunteers
No

Inclusion criteria

* Ages 0-90 years. * Any patient admitted to the hospital with burn injury requiring grafting and a donor site.

Exclusion criteria

* Patient with severe burn injuries expected to die.

Design outcomes

Primary

MeasureTime frame
epidermal regeneration (donor site healing)Days 3-14 post surgery

Secondary

MeasureTime frame
InfectionDays 0-21 post surgery
reduction in pain of donor siteDay 0-21 post surgery
ScarringDay 7 post surgery to 2 years post surgery
CostsAdmission post burn injury to 2 years post burn injury

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026